Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia.

Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia.

Item
http://www.wikidata.org/entity/Q45747274
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaRisk factors for medication non-adherence among psychiatric patients with substance misuse histories.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysisOnce-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia.Adherence to antipsychotic medication among homeless adults in Vancouver, Canada: a 15-year retrospective cohort study.Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States.Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illnessFactors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy
P2860

Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia.

Item
http://www.wikidata.org/entity/Q45747274
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Healthcare cost reductions ass ...... g patients with schizophrenia.
@en
Healthcare cost reductions ass ...... g patients with schizophrenia.
@nl
type
label
Healthcare cost reductions ass ...... g patients with schizophrenia.
@en
Healthcare cost reductions ass ...... g patients with schizophrenia.
@nl
prefLabel
Healthcare cost reductions ass ...... g patients with schizophrenia.
@en
Healthcare cost reductions ass ...... g patients with schizophrenia.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921
P356
P1433
P1476
Healthcare cost reductions ass ...... g patients with schizophrenia.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921